Skip to main content

The article reviews progress in the microRNA field over the past decade, and details findings in pre-clinical studies that have demonstrated that pharmacologic manipulation of microRNAs, mostly in the liver, can modulate metabolic phenotypes and even reverse the course of insulin resistance and diabetes.

Praveen Sethupathy, PhD
Praveen Sethupathy, PhD

Praveen Sethupathy, PhD, Assistant Professor in the Department of Genetics, published an invited review titled “The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic Diseases” in the June issue of Current Diabetes Reports. This review addresses progress in the microRNA field over the past decade and details findings in pre-clinical studies that have demonstrated that pharmacologic manipulation of microRNAs, mostly in the liver, can modulate metabolic phenotypes and even reverse the course of insulin resistance and diabetes.

Sethupathy writes “there is cautious optimism in the field about microRNA-based therapies for diabetes, several of which are already in various stages of clinical trials.” The review can be found at: http://link.springer.com/article/10.1007%2Fs11892-016-0745-3